Please login to the form below

Not currently logged in
Email:
Password:

Generics UK

This page shows the latest Generics UK news and features for those working in and with pharma, biotech and healthcare.

Lilly wins on appeal in Alimta vitamin regimen dispute

Lilly wins on appeal in Alimta vitamin regimen dispute

The ruling finds that Actavis generics on sale in the UK, France, Italy and Spain infringe on Lilly's patents for Alimta (pemetrexed disodium), which has lost patent protection in several ... directly infringe the patents, a decision which was upheld the

Latest news

  • Teva sells UK and Ireland assets to Intas Pharma for £603m Teva sells UK and Ireland assets to Intas Pharma for £603m

    Generics portfolio and manufacturing facility gain set to double Indian firm’ s UK sales. ... Offloading Actavis Generics UK and Irish assets is the latest in a series of divestments by Teva to meet antitrust conditions from international regulatory

  • Lundbeck challenge to EC pay-for-delay ruling fails Lundbeck challenge to EC pay-for-delay ruling fails

    Lundbeck challenge to EC pay-for-delay ruling fails. Court upholds 94m fine for paying off firms to delay launch of Celexa generics. ... The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around 52m, and those judgments

  • UK government fines GSK over 'pay-for-delay' deals UK government fines GSK over 'pay-for-delay' deals

    Actavis which have both been fined for the involvement of various generics units. ... Former Merck subsidiary Generics (UK) Ltd and Alpharma (acquired by Actavis in 2005) had been sued by GSK for patent infringement but the cases were dropped after the

  • No further price cut for non-PPRS drugs in UK No further price cut for non-PPRS drugs in UK

    Questions were also raised by the British Generic Manufacturers' Association (BGMA), which represents manufacturers and suppliers of generic drugs in the UK. ... Also weighing in was the Ethical Medicines Industry Group, representing the smaller drug

  • No further price cut for non-PPRS drugs in UK No further price cut for non-PPRS drugs in UK

    Questions were also raised by the British Generic Manufacturers' Association (BGMA), which represents manufacturers and suppliers of generic drugs in the UK. ... Also weighing in was the Ethical Medicines Industry Group, representing the smaller drug

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    Similarly the acquisition of Actavis (Allergan) Generics by Teva for $40.5bn has resulted in the divestment of Actavis's former factory and some products in the UK and Ireland to ... Teva (IS). Intas (IN). Asset Acquisition. Former Actavis generics

  • Pharma deals during January 2015 Pharma deals during January 2015

    This deal was of significance to Actavis as it gives the company the number 1 position for generics in the UK.

  • Proving value in uncertain times Proving value in uncertain times

    Additional pressure is being exerted in many EU markets with the introduction of new, additional barriers to access, whether it's the idea of value-based pricing in the UK or ... officially sanctioned generics prescribing targets in markets such as Spain,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Teva appoints UK & Ireland general manager Teva appoints UK & Ireland general manager

    Teva appoints UK &Ireland general manager. Promotes UK chief operating officer Kim Innes. ... She became head of Teva's generics business unit in the UK in 2006, before taking on her most recent position as chief operating officer in which she played a

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics